Integrating laboratory results with pharmacy claims provides the most rigorous measure of hepatitis C (HCV) treatment success, according to a cohort study published in JAMA Network Open. Researchers found that while direct-acting antivirals (DAAs) cure over 95% of infections, incomplete follow-up testing often leaves healthcare systems with an incomplete picture of patient outcomes. By combining data sources, providers can better track viral clearance and identify patients who may have been lost to follow-up.
Why Data Integration Matters for Hepatitis C Outcomes
Tracking the “care cascade”—the steps from initial diagnosis to sustained virologic response (SVR)—is essential for tracking progress towards hepatitis C elimination. A study led by H. Symum and colleagues analyzed data from the HealthVerity database for 91,491 US adults with evidence of HCV infection between 2019 and 2021. The research highlights that relying on a single data source, such as pharmacy records alone, often masks the true status of a patient’s health.
When researchers used integrated data—tracking both pharmacy-recorded treatment initiation and lab-confirmed viral clearance—they achieved the most rigorous assessment of success. However, the study noted that even this approach likely underestimates cure rates. The primary barrier is a lack of follow-up RNA testing; among the 18,246 individuals who started treatment, 23.2% had no subsequent RNA test to confirm if the virus was cleared.
Did you know? Sustained virologic response (SVR) is defined as having an undetectable HCV RNA level at least 12 weeks after finishing treatment. This is the clinical benchmark for declaring a patient cured.
The Challenge of Incomplete Follow-Up Testing
The gap between treatment initiation and confirmed cure remains a significant hurdle in public health. According to the study, 38.3% of patients with an initial HCV infection never underwent a follow-up RNA test. For those who did not have a recorded treatment initiation, 46.7% received no further testing, leaving their infection status unknown.
This “missing data” problem complicates efforts to eliminate the virus. While a negative RNA test is the strongest indicator of a cure, patients may clear the virus spontaneously or receive treatment that is not captured by insurance claims. Without integrated systems that bridge laboratory and pharmacy records, clinicians may fail to identify patients who remain at risk for advanced liver disease, liver cancer, or death.
Future Trends in Care Monitoring
The authors suggest that improving follow-up RNA testing and integrating laboratory and pharmacy data would enhance the accuracy of hepatitis C care monitoring and help identify gaps in testing and treatment.
Frequently Asked Questions
What is the most accurate way to measure hepatitis C cure?
The most rigorous method, according to the JAMA Network Open study, is combining laboratory data (to confirm viral clearance) with pharmacy records (to confirm treatment initiation).
Why is follow-up RNA testing often missed?
Many patients fail to return for follow-up testing after completing their DAA medication.
Can pharmacy records alone confirm a cure?
No. While pharmacy records indicate that a patient started treatment, they do not confirm that the virus was cleared. Laboratory-confirmed viral clearance is necessary to verify SVR.
Are you a healthcare provider or a patient navigating the HCV care cascade? Share your thoughts on how digital health tools can improve follow-up rates in the comments below. For more updates on liver health and infectious disease management, subscribe to our weekly newsletter.